T1	Participants 897 972	97 subjects (51 pitavastatin; 46 pravastatin) completed this 36-month study
T2	Participants 1162 1179	pravastatin group
T3	Participants 1086 1104	pitavastatin group
T4	Participants 1282 1319	pravastatin (-0.067 Â± 0.260 mm) group
T5	Participants 1233 1245	pitavastatin
T6	Participants 1417 1427	two groups
T7	Participants 1760 1768	subjects
